{"content":"<li class=\"n-box-item date-title\" data-end=\"1575781199\" data-start=\"1575694800\" data-txt=\"Monday, December 23, 2019\">Saturday, December  7, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3524623\" data-ts=\"1575751614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XBIT\" target=\"_blank\">XBIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524623-xbiotech-out-licenses-anti-inflammatory-antibody-to-janssen-for-up-to-1_35b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B</a></h4><ul><li>XBiotech (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIT' title='XBiotech Inc.'>XBIT</a>) inks an <a href=\"https://seekingalpha.com/pr/17721315-xbiotech-announces-agreement-to-sell-true-human-antibody-bermekimab-targeting-ilminus-1a-to\" target=\"_blank\">agreement </a>with Johnson &amp; Johnson (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) unit Janssen Biotech for global rights to anti-inflammatory candidate bermekimab.</li><li>Under the terms of the deal, XBIT will receive $750M upfront and up to $600M in milestones. It will also generate additional revenue over the next two years via a manufacturing supply and clinical services agreement with Janssen.</li><li>XBIT will use the proceeds to fund the advancement of its next generation True Human anti-IL-1\u237a antibody program, additional pipeline candidates and potential stock buybacks.</li><li><a href=\"http://www.xbiotech.com/clinical/dermatology.php\" target=\"_blank\">Bermekimab</a> is a monoclonal antibody that binds to (inhibits) the pro-inflammatory protein interleukin-1alpha (IL-1α).</li></ul><div class=\"tiny-share-widget\" data-id=\"3524623\" data-linked=\"XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B\" data-tweet=\"$XBIT $JNJ - XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B https://seekingalpha.com/news/3524623-xbiotech-out-licenses-anti-inflammatory-antibody-to-janssen-for-up-to-1_35b?source=tweet\" data-url=\"https://seekingalpha.com/news/3524623-xbiotech-out-licenses-anti-inflammatory-antibody-to-janssen-for-up-to-1_35b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":1,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}